G. Fendrich

发表

The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.

D. Fabbro, W. Jahnke, T. Meyer, 2005, Structure.

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.

Bhabatosh Chaudhuri, Doriano Fabbro, Pascal Furet, 2002, Pharmacology & therapeutics.

Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Journal of the American Chemical Society.

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

John T. Powers, G. Daley, W. Jahnke, 2010, Nature.

Imatinib: a selective tyrosine kinase inhibitor.

D. Fabbro, P. Furet, T. Meyer, 2002, European journal of cancer.

Amino–acid-type selective isotope labeling of proteins expressed in Baculovirus-infected insect cells useful for NMR studies

W. Jahnke, G. Fendrich, J. Liebetanz, 2003, Journal of biomolecular NMR.

The 2.5 A X‐ray crystal structure of the acid‐stable proteinase inhibitor from human mucous secretions analysed in its complex with bovine alpha‐chymotrypsin.

R. Huber, W. Bode, M. Grütter, 1988, The EMBO journal.

Mechanism of action of glutaryl-CoA and butyryl-CoA dehydrogenases. Purification of glutaryl-CoA dehydrogenase.

G. Fendrich, R. Abeles, B. Gomes, 1981, Biochemistry.

Mechanism of action of butyryl-CoA dehydrogenase: reactions with acetylenic, olefinic, and fluorinated substrate analogues.

G. Fendrich, R. Abeles, 1982, Biochemistry.

Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.

J. Mestan, D. Fabbro, P. Furet, 2004, Mini reviews in medicinal chemistry.

Improved expression of kinases in Baculovirus-infected insect cells upon addition of specific kinase inhibitors to the culture helpful for structural studies.

R. Schmitz, G. Fendrich, J. Liebetanz, 2007, Protein expression and purification.

On the Interaction Between p53 and MDM2: Transfer NOE Study of a p53-Derived Peptide Ligated to MDM2

C. García-echeverría, P. Chène, G. Fendrich, 1997 .

Nonlinear Broensted correlations: The roles of resonance, solvation, and changing transition-state structure

S. Brant, W. Jencks, G. Fendrich, 1982 .

Studies on glycollate oxidase from pea leaves determination of stereospecificity and mode of inhibition by α-hydroxybutynoate

G. Fendrich, S. Ghisla, 1982 .

Extended kinase profile and properties of the protein kinase inhibitor nilotinib.

J. Mestan, D. Fabbro, G. Martiny-Baron, 2010, Biochimica et biophysica acta.

Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib*♦

Wolfgang Jahnke, W. Jahnke, S. Grzesiek, 2008, Journal of Biological Chemistry.

L 3 Differences in the kinase binding modes of imatinib , nilotinib and dasatinib are reflected in Abl transphosphorylation assays

D. Fabbro, S. Grzesiek, S. Cowan-Jacob, 2009 .

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

Wolfgang Jahnke, Doriano Fabbro, Pascal Furet, 2010, Biochimica et biophysica acta.

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Donna Neuberg, Doriano Fabbro, Arghya Ray, 2005, Cancer cell.

Recombinant hirustasin: Production in yeast, crystallization, and interaction with serine proteases

M. Grütter, G. Fendrich, J. Priestle, 1997, Protein science : a publication of the Protein Society.

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia

Doriano Fabbro, Pascal Furet, D. Fabbro, 2006, Acta crystallographica. Section D, Biological crystallography.

Targeted Therapy with Imatinib: An Exception or a Rule?

J. Mestan, D. Fabbro, P. Furet, 2005 .

Bcr-Abl Binding Modes of Dasatinib, Imatinib and Nilotinib: An NMR Study.

W. Jahnke, S. Grzesiek, S. Cowan-Jacob, 2006 .

Chaperone over-expression in Escherichia coli: apparent increased yields of soluble recombinant protein kinases are due mainly to soluble aggregates.

M. Geiser, G. Fendrich, P. Ramage, 2009, Protein expression and purification.

Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib

W. Jahnke, S. Grzesiek, S. Cowan-Jacob, 2008, Biomolecular NMR assignments.

Efficient uniform isotope labeling of Abl kinase expressed in Baculovirus-infected insect cells

W. Jahnke, G. Fendrich, A. Strauss, 2005, Journal of biomolecular NMR.

The Crystal Structure of Cancer Osaka Thyroid Kinase Reveals an Unexpected Kinase Domain Fold*

N. Schmiedeberg, G. Fendrich, T. Troxler, 2015, The Journal of Biological Chemistry.

Purification, characterization and biological evaluation of recombinant leech-derived tryptase inhibitor (rLDTI) expressed at high level in the yeast Saccharomyces cerevisiae.

G. Fendrich, J. Heim, C. Sommerhoff, 1996, European journal of biochemistry.

Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors.

G. Martiny-Baron, G. Fendrich, T. Troxler, 2016, Journal of medicinal chemistry.

A new structural class of serine protease inhibitors revealed by the structure of the hirustasin-kallikrein complex.

M. Grütter, P. Mittl, G. Fendrich, 1997, Structure.

Refolding, isolation and characterization of crystallizable human interferon-α8 expressed in Saccharomyces cerevisiae

M. Grütter, G. Fendrich, S. D. Marco, 1996 .

Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain

D. Fabbro, W. Jahnke, S. Cowan-Jacob, 2011 .

Biological Crystallography Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukaemia

D. Fabbro, G. Rummel, P. Furet, 2022 .

Molecular Interactions between the Highly Selective pan-Bcr-Abl Inhibitor, AMN107, and the Tyrosine Kinase Domain of Abl.

J. Mestan, S. Cowan-Jacob, G. Fendrich, 2005 .

Inhibitors of Protein Kinases and Protein Phosphates Contributors

L. Meijer, D. Fabbro, M. Yacoub, 2005 .

Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site.

J. Mestan, D. Fabbro, W. Jahnke, 2010, Biochimica et biophysica acta.